Synergistic activity of magnolin combined with B-RAF inhibitor SB590885 in hepatocellular carcinoma cells via targeting PI3K-AKT/mTOR and ERK MAPK pathway.
ERK MAPK pathway
Magnolin
PI3K-AKT/mTOR pathway
SB590885
hepatocellular carcinoma cells
Journal
American journal of translational research
ISSN: 1943-8141
Titre abrégé: Am J Transl Res
Pays: United States
ID NLM: 101493030
Informations de publication
Date de publication:
2019
2019
Historique:
received:
09
03
2019
accepted:
06
05
2019
entrez:
18
7
2019
pubmed:
18
7
2019
medline:
18
7
2019
Statut:
epublish
Résumé
The prognosis of patients with advanced hepatocellular carcinoma (HCC) remains obscure. From a clinical point of view, the ERK MAPK pathway and the PI3K/AKT pathway are activated in the majority of liver cancer. In addition, long term used to single agent treatment of HCC, frequently results in reverse activation of the ERK MAPK pathway or the PI3K/AKT pathway, leading to drug resistance. Thus, it is important to research the mechanism of combination agents that could suppress different pathways to treat HCC. Here, we found that combination natural product magnolin with BRAF inhibitor SB590885 synergistically suppressed the proliferation, promoted cell cycle arrest and apoptosis in hepatocellular carcinoma cells Bel-7402 and SK-Hep1. Furthermore, we demonstrated that the magnolin and the SB590885 combination led to increased impaired proliferation via inhibition of the ERK MAPK pathway and the PI3K/AKT pathway. These findings highlight the important role of agent combination and provided the approaches of therapeutic improvement for patients with advanced HCC.
Types de publication
Journal Article
Langues
eng
Pagination
3816-3824Déclaration de conflit d'intérêts
None.
Références
Gastroenterology. 2001 Jun;120(7):1763-73
pubmed: 11375957
Biol Pharm Bull. 2001 Sep;24(9):1085-7
pubmed: 11558575
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Cancer Res. 2008 Aug 15;68(16):6779-88
pubmed: 18701503
Surg Clin North Am. 2009 Feb;89(1):97-113, ix
pubmed: 19186233
Phytother Res. 2010 May;24(5):748-53
pubmed: 19943243
J Pharmacol Exp Ther. 2011 Apr;337(1):155-61
pubmed: 21205925
N Engl J Med. 2011 Sep 22;365(12):1118-27
pubmed: 21992124
Biochem Biophys Res Commun. 2012 Jan 13;417(2):771-6
pubmed: 22197821
Carcinogenesis. 2014 Feb;35(2):432-41
pubmed: 24031026
J Hepatol. 2014 Apr;60(4):855-65
pubmed: 24308993
Oncol Rep. 2014 Feb;31(2):573-80
pubmed: 24337632
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
pubmed: 24399786
Eur J Pharm Biopharm. 2014 Sep;88(1):216-25
pubmed: 24813390
Invest New Drugs. 2014 Aug;32(4):626-35
pubmed: 24821574
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Cancer Epidemiol. 2015 Jun;39(3):284-90
pubmed: 25922178
J Cell Mol Med. 2015 Sep;19(9):2244-52
pubmed: 26081844
BMC Cancer. 2015 Aug 08;15:576
pubmed: 26253302
Prostate. 2015 Dec;75(16):1896-903
pubmed: 26306811
PLoS One. 2015 Sep 18;10(9):e0138485
pubmed: 26381511
Mol Cancer Ther. 2016 Nov;15(11):2553-2562
pubmed: 27496136
Onco Targets Ther. 2016 Nov 09;9:6843-6855
pubmed: 27877053
Biomed Pharmacother. 2017 Mar;87:714-720
pubmed: 28092770
Cell Death Dis. 2018 Jun 13;9(6):702
pubmed: 29899555
Mol Carcinog. 2019 Jan;58(1):88-101
pubmed: 30230030
Adv Enzyme Regul. 1984;22:27-55
pubmed: 6382953